1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

• DOI: 10.1016/j.annonc.2021.08.1488
• Publication Date: 2021-09-21T19:07:41Z
• Authors: D.V. Catenacci; H. Park; B.Y. Shim; S.T. Kim; D-Y. Oh; A. Spira; S. Ulahannan; E.J. Avery; P.M. Boland; J. Chao; H.C. Chung; F. Gardner; S.J. Klempner; K-W. Lee; S.C. Oh; J. Peguero; M.B. Sonbol; J. Sun; M.K. Rosales; Y-K. Kang
• Keywords: Clinical endpoint